Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment
Standard
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment. / Bauer, Emanuel C A; Schochter, Fabienne; Widschwendter, Peter; DeGregorio, Amelie; Andergassen, Ulrich; Friedl, Thomas W P; Fasching, Peter A; Fehm, Tanja; Schneeweiss, Andreas; Beckmann, Matthias W; Pantel, Klaus; Janni, Wolfgang; Rack, Brigitte; Scholz, Christoph; SUCCESS Study Group.
in: BREAST CANCER RES TR, Jahrgang 171, Nr. 3, 10.2018, S. 571-580.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment
AU - Bauer, Emanuel C A
AU - Schochter, Fabienne
AU - Widschwendter, Peter
AU - DeGregorio, Amelie
AU - Andergassen, Ulrich
AU - Friedl, Thomas W P
AU - Fasching, Peter A
AU - Fehm, Tanja
AU - Schneeweiss, Andreas
AU - Beckmann, Matthias W
AU - Pantel, Klaus
AU - Janni, Wolfgang
AU - Rack, Brigitte
AU - Scholz, Christoph
AU - SUCCESS Study Group
PY - 2018/10
Y1 - 2018/10
N2 - PURPOSE: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.METHODS: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch® System (Veridex, USA) 2 and 5 years after primary diagnosis.RESULTS: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up.CONCLUSIONS: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence.
AB - PURPOSE: Several studies have provided evidence on the prognostic relevance of circulating tumor cells (CTCs) detected before and after chemotherapy regarding overall survival (OS) and progression-free survival (PFS) in early breast cancer (EBC). We provide data on the prevalence of CTCs 2 and 5 years after primary diagnosis in a cohort of patients with EBC.METHODS: The SUCCESS study is a multicenter, prospective, randomized trial comparing PFS in primary breast cancer patients undergoing one of two adjuvant chemotherapy regimens followed by 2 versus 5 years of treatment with zoledronate. CTCs from patients without signs of breast cancer recurrence were analyzed in peripheral blood using the FDA cleared CellSearch® System (Veridex, USA) 2 and 5 years after primary diagnosis.RESULTS: CTCs were detected at 2 and 5 years after primary diagnosis in 96 (16.7%) and 47 (8.2%) of the 574 patients, respectively. There were no associations between CTC status and patient and tumor characteristics or treatment regimens. In 442 (77.0%) patients, no CTCs were detected at either of the two time points, and in 11 patients (1.9%), CTCs were found at both 2 and 5 years after primary diagnosis. In 85 (14.8%) patients, CTCs were present 2 years after primary diagnosis but not after 5 years, while 36 (6.3%) patients had CTCs in their blood only at the 5-year follow-up.CONCLUSIONS: In patients with EBC, CTCs can be detected even 5 years after primary diagnosis without clinical signs of disease recurrence.
KW - Journal Article
U2 - 10.1007/s10549-018-4856-1
DO - 10.1007/s10549-018-4856-1
M3 - SCORING: Journal article
C2 - 29931425
VL - 171
SP - 571
EP - 580
JO - BREAST CANCER RES TR
JF - BREAST CANCER RES TR
SN - 0167-6806
IS - 3
ER -